Clinical Trial Update: IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the IXO combination (Irinotecan, Capecitabine, and Oxaliplatin) in rectal cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Rectal Cancer | Phase 2 | Status: UNKNOWN